Table 3b.

Hazard ratios for clinically significant predictors of major outcomes after single and double UCBT

Single UCBT
	Overall Survival	Disease-Free Survival	Relapse	Non-Relapse Mortality	Chronic GVHD
Gr. II–IV Acute GVHD			0.69 (0.51–0.93) p=0.014	2.06 (1.47–2.88) p<0.0001	2.02 (1.51–2.70) p<0.0001
Primary Disease1	0.73 (0.58 – 0.91) p=0.0054	0.71 (0.57–0.89) p=0.0024
Disease Status at Transplant2	1.37 (1.06 – 1.76) 2.89 (2.14–3.91) p<0.0001	1.32 (1.03–1.68) 2.58 (1.90–3.50) p<0.0001	1.57 (1.12–2.21) 4.88 (3.28–7.27) p<0.0001
CMV Positivity	1.47 (1.19–1.82) p=0.0003	1.45 (1.17–1.79) p=0.0006		1.77 (1.27–2.46) p=0.0008
Age3			0.77 (0.56–1.07) 0.61 (0.41–0.89) p=0.011	1.40 (0.95–2.07) 2.03 (1.37–3.01) p=0.0018
Absence of ATG			1.49 (1.08–2.07) p=0.016	0.44 (0.30–0.66) p<0.0001
TBI Use			0.59 (0.43–0.81) p=0.0013
Double UCB
	Overall Survival	Disease-Free Survival	Relapse	Treatment-Related Mortality	Chronic GVHD
Gr. II–IV Acute GVHD					2.12 (1.52–2.95) p<0.0001
Primary Disease1	1.02 (0.81–1.28) 1.86 (1.39–2.48) p<0.0001
Disease Status at Transplant2		1.02 (0.81–1.28) 1.56 (1.12–2.18) p=0.022	1.42 (1.01–2.00) 3.56 (2.27–5.57) p<0.0001
TBI Use		0.73 (0.55–0.97) p=0.032	0.67 (0.45–1.00) p=0.049
Karnofsky Performance Status4	0.71 (0.57–0.89) p=0.0028	0.77 (0.61–0.97) p=0.024		0.66 (0.48–0.90) p=0.0095
Conditioning Regimen5		1.36 (1.10–1.69) p=0.0048	2.53 (1.84–3.47) p<0.0001	0.59 (0.40–0.87) p=0.0083
Age3				1.28 (0.88–1.87) 1.83 (1.17–2.86) p=0.029

Hazards for each relationship presented, p values for entire trend presented

¹ALL vs AML

²Intermediate vs. Early, Advanced vs. Early

³Age 5–9 vs. 0–4 and 10–17 vs. 0–4 for single UCBT; Age 18–29 vs. 30–49 vs. 50+ for double UCBT

⁴Karnofsky performance status < 90 vs 90–100

⁵Redcued Intensity vs. Myeloablative